Liedekerke advises HERAN Partners and LUMO Labs on €5 million seed investment in Nuclivision
Category: Deal Announcement
Liedekerke has advised HERAN Partners and LUMO Labs on their €5 million seed round investment in Nuclivision BV, a Belgian company developing and commercialising AI-driven software solutions for nuclear medicine applications.
Nuclivision’s flagship product, Nuclarity, enhances PET imaging to deliver greater accuracy, safety, and accessibility in the field of oncology and theranostics. This investment will allow Nuclivision to scale operations and accelerate the deployment of its technology across Europe and the United States.
Our team provided full-service legal support to the lead investors, including:
Drafting and negotiation of the term sheet,
High-level red flag due diligence,
Drafting and negotiation of transaction documents (share subscription agreement, shareholders’ agreement, ancillary documentation),
Coordination with the notary for the contributions in kind and in cash, including the issuance of indemnification and anti-dilution rights.
This transaction underlines Liedekerke’s strong expertise in advising on venture capital investments, particularly in the HealthTech and AI sectors.
We are proud to have supported HERAN Partners and LUMO Labs on this exciting project and congratulate all parties involved.
For more information, please contact our team.